Get the Stockscreener App
1.78
29.93%
0.41
After Hours:
1.82
0.04
+2.25%
Zentalis Pharmaceuticals Inc stock is traded at $1.78, with a volume of 9.01M.
It is up +29.93% in the last 24 hours and up +28.06% over the past month.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
See More
Previous Close:
$1.37
Open:
$1.37
24h Volume:
9.01M
Relative Volume:
10.92
Market Cap:
$128.61M
Revenue:
-
Net Income/Loss:
$-292.19M
P/E Ratio:
-0.3921
EPS:
-4.54
Net Cash Flow:
$-208.41M
1W Performance:
+33.83%
1M Performance:
+28.06%
6M Performance:
+41.27%
1Y Performance:
-43.13%
1-Day Range:
$1.37
$2.03
1-Week Range:
$1.31
$2.03
52-Week Range:
$1.01
$3.19
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Name
Zentalis Pharmaceuticals Inc
Sector
Industry
Phone
(858) 263-4333
Address
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Compare ZNTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
1.78 | 98.98M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-24 | Upgrade | Wedbush | Underperform → Neutral |
| Jun-20-24 | Downgrade | UBS | Buy → Neutral |
| Jun-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jun-18-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-18-24 | Downgrade | Wedbush | Neutral → Underperform |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-08-23 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-07-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-12-22 | Initiated | Cowen | Outperform |
| Apr-06-22 | Initiated | Wells Fargo | Overweight |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-29-21 | Initiated | Oppenheimer | Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Jan-20-21 | Initiated | Wedbush | Outperform |
| Sep-29-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Apr-28-20 | Initiated | Guggenheim | Buy |
| Apr-28-20 | Initiated | Jefferies | Buy |
| Apr-28-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Initiated | SVB Leerink | Outperform |
View All
Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News
What drives Zentalis Pharmaceuticals Inc stock priceGap Fill Strategies & Double Or Triple Capital - earlytimes.in
ZNTL Pharmaceuticals Updates on Azenosertib Development - GuruFocus
Zentalis Pharmaceuticals Provides Corporate Update and - GlobeNewswire
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of “Hold” by Brokerages - Defense World
Will Zentalis Pharmaceuticals Inc. stock outperform growth indexes2025 Price Action Summary & Verified Swing Trading Watchlists - Улправда
Will Zentalis Pharmaceuticals Inc. stock maintain momentum in 2025Weekly Profit Recap & Free Growth Oriented Trading Recommendations - Bölüm Sonu Canavarı
Will Zentalis Pharmaceuticals Inc. stock see PE expansionWeekly Risk Report & AI Powered Buy/Sell Recommendations - DonanımHaber
Is Zentalis Pharmaceuticals Inc. stock a top pick in earnings season2025 Market Sentiment & AI Forecast for Swing Trade Picks - DonanımHaber
Why Zentalis Pharmaceuticals Inc. stock is favored by top institutions2025 Key Highlights & Consistent Income Trade Ideas - Улправда
Zentalis Pharmaceuticals Earnings Notes - Trefis
Incyclix Bio Expands Board of Directors with Appointment of Dr. Kimberly Blackwell - GlobeNewswire Inc.
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Matrix Capital Management Comp Sells 7,500,000 Shares of Stock - Defense World
Insider Selling: Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Sells 7,500,000 Shares of Stock - MarketBeat
Zentalis Pharmaceuticals (ZNTL) director reports 7,500,000 share sale - Stock Titan
[8-K] Zentalis Pharmaceuticals, Inc. Reports Material Event | ZNTL SEC FilingForm 8-K - Stock Titan
Oppenheimer cuts Zentalis stock target to $10, maintains rating - MSN
Zentalis Pharmaceuticals: Late Stage, Lots Of Cash, Crushed By The Market - Seeking Alpha
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Zentalis Pharma (ZNTL) Stock Analysis Report | Financials & Insights - Benzinga
Can Zentalis Pharmaceuticals Inc. stock surprise with earnings upside2025 Volume Leaders & Reliable Entry Point Alerts - Newser
An analyst sees good growth prospects for Zentalis Pharmaceuticals Inc (ZNTL) - setenews.com
We're Keeping An Eye On Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Rate - Yahoo Finance
Is Zentalis Pharmaceuticals Inc. stock a safe haven asset2025 Risk Factors & Long-Term Growth Portfolio Plans - Newser
New Highs: Will Zentalis Pharmaceuticals Inc stock outperform growth indexesMarket Risk Report & Risk Controlled Stock Pick Alerts - BỘ NỘI VỤ
Is Zentalis Pharmaceuticals Inc. stock safe for conservative investorsJuly 2025 Summary & Free Daily Entry Point Trade Alerts - Newser
Are Bears Losing Grip on Artson LimitedMarket Capitalization Trends & Reduce Losses With Smart Exit Strategies - earlytimes.in
Is Zentalis Pharmaceuticals Inc. stock trading near support levels2025 Pullback Review & Long-Term Growth Stock Strategies - BỘ NỘI VỤ
Zentalis Pharmaceuticals Forms Death Cross, Signaling Bearish Trend Ahead - Markets Mojo
Perhaps timely catching Zentalis Pharmaceuticals Inc (ZNTL) would be a good idea - Setenews
Connor Clark & Lunn Investment Management Ltd. Decreases Stake in Zentalis Pharmaceuticals, Inc. $ZNTL - Defense World
Zentalis Pharmaceuticals (ZNTL) Price Target Decreased by 14.14% to 5.42 - MSN
What indicators show strength in Zentalis Pharmaceuticals Inc.Portfolio Growth Summary & Accurate Entry and Exit Point Alerts - newser.com
Is Zentalis Pharmaceuticals Inc. stock in correction or buying zoneMarket Volume Summary & Free Verified High Yield Trade Plans - newser.com
Why analysts upgrade Zentalis Pharmaceuticals Inc. stockEarnings Performance Report & Weekly Setup with High ROI Potential - newser.com
Why Zentalis Pharmaceuticals Inc. stock is in analyst buy zone2025 Analyst Calls & AI Driven Stock Reports - newser.com
Is Zentalis Pharmaceuticals Inc. forming a bottoming base2025 Top Decliners & Reliable Price Breakout Alerts - newser.com
Zentalis Pharmaceuticals: Hanging On For One Last Shot At PROC Approval (ZNTL) - Seeking Alpha
Multi asset correlation models including Zentalis Pharmaceuticals Inc.Earnings Beat & Weekly High Conviction Trade Ideas - newser.com
How geopolitical tensions affect Zentalis Pharmaceuticals Inc. stockBuy Signal & Momentum Based Trading Ideas - newser.com
Wall Street Zen Upgrades Zentalis Pharmaceuticals (NASDAQ:ZNTL) to Hold - MarketBeat
Can Zentalis Pharmaceuticals Inc. stock reach $100 price target2025 Key Highlights & Weekly High Return Stock Opportunities - newser.com
Zentalis Pharmaceuticals Inc Stock (ZNTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zentalis Pharmaceuticals Inc Stock (ZNTL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Myers Scott Dunseth | Director |
Apr 30 '25 |
Buy |
1.40 |
21,000 |
29,373 |
281,192 |
| Bruns Ingmar | Chief Medical Officer |
Feb 06 '25 |
Buy |
2.28 |
20,000 |
45,656 |
36,629 |
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):